PT - JOURNAL ARTICLE AU - Drobniewski, Francis AU - Kusuma, Dian AU - Broda, Agnieszka AU - Castro-Sánchez, Enrique AU - Ahmad, Raheelah TI - COVID-19 vaccine hesitancy in diverse groups in the UK - is the driver economic or cultural in student populations? AID - 10.1101/2021.12.14.21267773 DP - 2022 Jan 01 TA - medRxiv PG - 2021.12.14.21267773 4099 - http://medrxiv.org/content/early/2022/02/11/2021.12.14.21267773.short 4100 - http://medrxiv.org/content/early/2022/02/11/2021.12.14.21267773.full AB - Studies have identified a greater reluctance for members of the Black, Asian, and minority ethnic communities to be vaccinated against COVID-19 despite a higher probability of greater harm from COVID-19. We conducted an anonymised questionnaire-based study of students (recruiting primarily before first reports of embolic events) at two London universities to identify whether economic or educational levels were primarily responsible for this reluctance: a postgraduate core group (PGCC) n=860 and a pilot study of undergraduate medical and nursing students (n=103). Asian and Black students were 2.0 and 3.2 times (PGCC) less likely to accept the COVID vaccine than White British students. Similar findings were noted in the pilot study students. As students were studying for Masters or PhD degrees and voluntarily paying high fees, educational and economic reasons were unlikely to be the underlying cause, and wider cultural reservations were more likely. Politicians exerted a strong negative influence, suggesting that campaigns should omit politicians.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was partially funded by Horizon Europe grant No. 101046016 EuCARE: European Cohorts of Patients and Schools to Advance Response to Epidemics. FD is supported by the NIHR Imperial Biomedical Research Centre. RA, as Knowledge Mobilisation Lead, acknowledges the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College London in partnership with the UK Health Security Agency (previously PHE), and in collaboration with, Imperial Healthcare Partners, University of Cambridge and University of Warwick. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR or the NHS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics was obtained from the Imperial College Research Ethics Committee (Ref: 21IC6546) and City University Research Ethics Committee (Ref: ETH2021-0904). Informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://imperial.eu.qualtrics.com/jfe/form/SV_0xilN8FYXeabREW